LATEST #ATS2023 NEWS


  • Trials Show Promise for New Agents to Treat COPD

    Trials Show Promise for New Agents to Treat COPD

    Several trial results for the treatment of COPD were shared at the 2023 International Conference. Gerard J. Criner, MD, and David M. Mannino III, MD, discussed findings from the BOREAS trial, expectations from the ongoing NOTUS trial, and data from the ENHANCE-1 and ENHANCE-2 studies.

    Read More



  • Ongoing Trials, Genetic Breakthroughs Pave the Way for Progress in Bronchiectasis

    Ongoing Trials, Genetic Breakthroughs Pave the Way for Progress in Bronchiectasis

    Timothy R. Aksamit, MD, FCCP, and Mark Metersky, MD, FCCP, comment on updates from multiple studies making headway in treating bronchiectasis. These trials, presented at the ATS 2023 International Conference, reflect research focusing on the three pillars of the disease: infection, inflammation, and mucociliary milieu. The trials included phase three of PROMIS II and phase…

    READ MORE


  • Researchers Report Positive Trial Results on Four Investigative Agents for Asthma, COPD, and PAH

    Researchers Report Positive Trial Results on Four Investigative Agents for Asthma, COPD, and PAH

    Four highly anticipated trials were presented at the ATS 2023 International Conference. The trials included the TORREY Study of Seralutinib, the ENHANCE Trials of Nebulized Ensifentrine, the Phase 1b Study of SAR443765 in Mild-to-Moderate Asthma, and the BOREAS Study of Dupilumab in COPD Patients with Type 2 Inflammation. Robert P. Frantz, MD, summarized the findings…

    READ MORE


  • Clinical Year in Review 3 Focuses on Asthma, Sarcoidosis, Sepsis, Sleep

    Clinical Year in Review 3 Focuses on Asthma, Sarcoidosis, Sepsis, Sleep

    The third session of the annual Clinical Year in Review explored the latest developments in asthma, sarcoidosis, sepsis, and sleep. Using Single Maintenance and Reliever Therapy recommendations for patients with asthma addresses issues of self-management and adherence often seen in this population, reported Vanessa Marie McDonald, PhD.

    READ MORE